Pharmacy Benefit Manager (PBM)

A Pharmacy Benefit Manager (PBM) is a third-party company that administers prescription drug benefits on behalf of health plans, employers, and government programs. The three largest PBMs — CVS Caremark, Express Scripts (Cigna), and OptumRx (UnitedHealth) — collectively manage prescription benefits for roughly 80 percent of insured Americans. PBMs negotiate drug prices with manufacturers, develop and manage formularies, process pharmacy claims, and operate mail-order and specialty pharmacy networks.

The PBM business model is built on multiple revenue streams that are frequently misunderstood or invisible to employers: rebates negotiated from drug manufacturers (which the PBM retains a share of before passing the remainder to the plan), spread pricing (where the PBM charges the plan more for a drug than it pays the pharmacy and keeps the difference), administrative fees, and data licensing. The opacity of these arrangements has been the subject of increasing regulatory scrutiny, FTC investigations, and Congressional hearings. The fundamental problem is a conflict of interest: PBMs have financial incentives to favor high-list-price, high-rebate drugs over lower-cost alternatives that might serve the patient better at lower total cost. A drug with a $500 list price and a $200 manufacturer rebate generates more PBM revenue than a $150 generic — even if the generic is therapeutically equivalent. Transparent-model PBMs have emerged in response, passing 100 percent of rebates to the plan and charging a flat administrative fee per claim instead, making the economics visible and eliminating the conflict. Employers considering a PBM audit or carve-out should start by requesting a complete disclosure of all rebates retained, spread on each claim, and any affiliated pharmacy revenue.

The takeaway: your PBM is not a neutral administrator — it's a for-profit company with incentive structures that may not align with your plan's goal of delivering the best drug at the lowest cost. Request a full contract audit annually, ask for 100 percent rebate pass-through, and benchmark your effective drug costs against a transparent-model alternative before assuming your current PBM arrangement is optimized.